Wedge Capital Management L L P NC Has $41.43 Million Stake in DaVita Inc. $DVA

Wedge Capital Management L L P NC decreased its holdings in shares of DaVita Inc. (NYSE:DVA) by 22.8% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 186,227 shares of the company’s stock after selling 55,101 shares during the quarter. Wedge Capital Management L L P NC’s holdings in DaVita were worth $41,432,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Root Financial Partners LLC boosted its position in DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after acquiring an additional 105 shares during the period. Caitlin John LLC acquired a new position in shares of DaVita in the 4th quarter valued at about $34,000. Sankala Group LLC acquired a new position in shares of DaVita in the 4th quarter valued at about $39,000. Canada Pension Plan Investment Board purchased a new stake in shares of DaVita in the second quarter worth approximately $43,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of DaVita in the fourth quarter worth approximately $45,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.90% of the stock is owned by corporate insiders.

DaVita Stock Down 3.0%

NYSE DVA opened at $178.25 on Wednesday. The company has a 50 day moving average price of $218.11 and a two-hundred day moving average price of $178.10. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $247.49. The stock has a market capitalization of $11.37 billion, a PE ratio of 14.59, a price-to-earnings-growth ratio of 0.61 and a beta of 0.88.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.88 by $0.14. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts anticipate that DaVita Inc. will post 14.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on DVA. Barclays boosted their price objective on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. UBS Group increased their target price on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Weiss Ratings upgraded shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Finally, Raymond James Financial set a $220.00 price target on shares of DaVita in a research note on Friday. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $221.75.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.